Nav: Home

Prophylactic cranial irradiation: Improvements for advanced NSCLC

March 18, 2019

Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients.

Cumulative brain metastases (BM) rates are high for patients with LA-NSCLC. NRG Oncology conducted the NRG-RTOG 0214 trial to address this high incidence of brain metastases and determine if the addition of PCI following primary treatment improved overall survival (OS) in patients with LA-NSCLC. This trial also evaluated changes in disease-free survival (DFS) and brain metastases rates. At 5 and 10 years, PCI did not improve survival in patients with stage III LA-NSCLC without progression of disease after therapy, however, DFS increased and BM rates decreased considerably, thus providing important information that could benefit future trials. The long-term update of this trial was recently published in JAMA Oncology.

Patients in NRG-RTOG 0214 were randomly assigned either to observation or to receive PCI in 2Gy per fraction over five days a week up to 30Gy. This occurred at 291 institutions globally. Patients in the PCI study arm were followed beginning at 3 and 6 months from the start of PCI, then every 6 months for 2 years, then yearly. Brain imaging with MRI or CT was performed at 6 and 12 months, then yearly

340 patients were evaluable at 5 and 10 years. OS rates on the study arm that received PCI were not statistically better than the observation arm (HR=0.82, p= 012, 10-year rates: 17.6% and 13.3%, respectively), however, DFS improved significantly (HR=0.76, p= 003, 10-year rates 12.6% vs. 7.5% for PCI vs. observation) as well as BM rates (p=0004, 10-year rates 16.7% vs. 28.3% for PCI vs. observation). Patients in the PCI study arm were 57% less likely to develop BM than those in the observation arm (HR=0.43, 95% CI=0.24-0.77).

A subgroup analysis of 225 patients on this trial who did not have surgery of their primary lung tumor exhibited statistically significant differences in OS, DFS, and BM rates between the PCI treatment arm and the observation arm. This analysis suggests PCI may prolong OS in this subgroup, as the median survival time of 2.3 years on the PCI arm compared favorably to 1.9 years on the observation arm (p=0.027). Multivariable analysis within this patient population suggests PCI may effectively prolong OS (HR=0.73, p=004) and DFS (HR=0.70, p=001), and decreases BM (HR=0.34, p=0002).

"As the incidence of brain metastases rise in patients living longer with improved control of loco-regional and distant disease, the need to establish an accepted means of prevention of brain metastases remains important. Researchers need to identify the appropriate patient population and a safe intervention on future trials," stated Alexander Sun, MD, of the Department of Radiation Oncology at the University Health Network's Princess Margaret Cancer Centre and corresponding author of NRG-RTOG 0214.
-end-
This project was supported by grants U10CA21661 (RTOG-Ops-Stat ), U10CA180822 (NRG Oncology SDMC), U10CA180868 (NRG Oncology Operations) and U10CA37422 (CCOP) from the National Cancer Institute (NCI).

Citation

Sun A, Hu C, Wong SJ, Gore E, Videtic G, Dutta S, Suntharalingam M, Chen Y, Gaspar LE, Choy H. Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019 Mar 14. doi: 10.1001/jamaoncol.2018.7220. [Epub ahead of print] PubMed PMID: 30869743.

About NRG Oncology

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology's extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trials Network.

http://www.nrgoncology.org

NRG Oncology

Related Brain Metastases Articles:

No difference in pain response between SBRT and conventional RT for patients with spinal metastases
A Phase III, NRG Oncology clinical trial that compared radiosurgery (SRS) or stereotactic body radiotherapy (SBRT) to the conventional radiotherapy (cEBRT) for patients with spinal metastases indicated that there was no statistically significant difference between the treatments for pain response, adverse events, FACT-G, BPI, and EQ-5D scores.
Nanoparticle therapy targets lymph node metastases
Metastasis, in which cancer cells break free from the primary tumor and form tumors at other sites, worsens the prognosis for many cancer patients.
No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases
The results of the ECOG-ACRIN Cancer Research Group's phase three trial, E2810, show no disease-free survival benefit with the use of one year of pazopanib in patients with metastatic renal cell carcinoma (kidney cancer) who had no evidence of disease following surgery to remove further metastases.
Bone cells suppress cancer metastases
A subpopulation of bone cells releases factors that can halt the growth of breast cancer that's traveled to the bone, putting the cells in stasis.
Study finds melanoma brain metastases are immunosuppressive with treatment-resistant metabolism
Melanoma tumors that have spread to the brain are equipped to thwart immunotherapies and targeted therapies that succeed against tumors growing in other sites.
More Brain Metastases News and Brain Metastases Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...